AGIO241220P75000
- 13.41
- 0.000.00%
Agios Pharmaceuticals Newsroom
The Best U.S. Value Stocks by Quant: AGIO, DLX, PPC
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticalsto Overweight
The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Here's Why Agios Stock Plummeted More Than 20% on Monday
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $75
RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating
Small U.S. Stocks Decrease; Agios Pharmaceuticals Posts Biggest Loss
Agios Pharmaceuticals Down Nearly 22%, on Pace for Record Percent Decrease -- Data Talk
Agios Pharmaceuticals Analyst Ratings
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Agios Reports Results From Late-stage Study of Its Thalassemia Treatment
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $75
Express News | Agios Pharmaceuticals Inc : Scotiabank Raises Target Price to $75 From $53
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals
Express News | Agios Pharmaceuticals - Filed Regulatory Applications for Mitapivat US, EU, Saudi Arabia ,UAE
Agios Presents Positive Results From Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
Express News | Agios Presents Positive Results From Phase 3 Energize-T Study of Mitapivat at Ash 2024 and Provides Regulatory Update on Mitapivat